Pfizer’s Daurismo (glasdegib) Receives FDA Approval for Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML)

 Pfizer’s Daurismo (glasdegib) Receives FDA Approval for Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML)

Pfizer’s Daurismo (glasdegib) Receives FDA Approval for Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML)


Shots:

  • The approval is based on P-II BRIGHT (1003) trial study results assessing Daurismo + cytarabine (LDAC) & daunorubicin vs PBO + cytarabine & daunorubicin in 115 patients in ratio (2:1) with newly diagnosed AML
  • The P-II BRIGHT (1003) study resulted in median OS 8.3 mos and 54% reduction in the risk of death for patients
  • Daurismo (glasdegib) is an oral qd Hedgehog pathway inhibitor indicated for the treatment of patients with newly diagnosed AML in adult patients who are >75 years

Click here to read full press release/ article | Ref: Pfizer | Image: Twitter

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post